4Moving Biotech

Executive Summary

4Moving Biotech is a French clinical-stage company pioneering a novel approach to osteoarthritis (OA) by targeting low-grade inflammation with GLP-1 analogs. Its lead candidate, 4P004, leverages the anti-inflammatory properties of GLP-1 receptor agonists, inspired by the work of rheumatologist Prof. Francis Berenbaum. Unlike conventional OA treatments that focus on symptom relief, 4P004 aims to modify disease progression. The company integrates artificial intelligence, real-world data, and innovative trial designs to accelerate development. Currently in Phase 2, 4Moving represents a unique opportunity in the OA space, which lacks disease-modifying drugs and has a large aging population. The platform could also be extended to other inflammatory conditions. With a strong scientific foundation and a differentiated mechanism, 4Moving is well-positioned to address a significant unmet need. However, as a private company with limited disclosure, the risk profile is elevated. The conviction score reflects the early stage and sparse public data, but the therapeutic potential justifies attention.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 Top-Line Data Readout for 4P00455% success
• H2 2026Strategic Partnership or Licensing Deal40% success
• Q3 2026Regulatory Update or Fast Track Designation25% success